GV-971 plays its anti-Alzheimer's role by targeting gut bacteria

September 6th, the
Research Group of Geng Meiyu of the Shanghai Pharmaceutical Research Institute of China, in collaboration with the research team of the Green Valley Pharmaceutical Research Institute in Shanghai, published a research paper entitled Sodium oligomannate therapeutically remodels gut microbiota and suppresses guts gutzing aminino acids-shaped neuroinflammation to Alzheimer's disease. AD) During the onset of the disease, intestinal bacteriologic disorders can induce inflammation of nerves in the brain, leading to AD cognitive impairment, and GV-971, china's first oligosaccharide anti-AD drug, can play its therapeutic role in AD by regulating the intestinal bacteriologic group.
this study not only confirms the hypothesis in the field of research on the association between intestinal bacteri group disorders and AD, but also provides for the first time the specific molecular mechanisms of AD intestinal bacteria disorders that induce nerve inflammation in the brain. The team found that intestinal bacterium disorders cause abnormalities in metabolites, including essential amino acids such as phenylalanine and isoleminine, which are released into the outer bloodstream, which promotes the differentiation and proliferation of outer immune cells such as Th1 cells, which in turn increases the intrusion of external pro-inflammatory Th1 and other immune cells into the brain, inducing inflammation of the brain nerves, leading to AD cognitive dysfunction.
Further studies have found that GV-971, an original oligosaccharide anti-AD drug in China, improves cognitive dysfunction by reshaping the balance of the intestinal bacteria, reducing the production of metabolites of the intestinal bacterium, especially phenylalanine and isoestine, reducing inflammation of the outer and central regions, and reducing the deposition of A-beta and Tau excessive phosphatization in the brain. In addition, Geng Meiyu team also found that GV-971 can directly through the blood-brain barrier, through multiple points, multi-fragments, multi-state capture of A beta, inhibit the formation of A-beta filament, and the formation of filaments disintegration into non-toxic monomer.
this unique mechanism of action gives GV-971 a completely different clinical efficacy and safety characteristics from existing drugs, and provides an important scientific basis for a deep understanding of the continuous and robust improvement of clinical cognitive function in phase III of GV-971. The above research provides a new research perspective to clarify the pathogenesis of AD complex diseases and a new research and development strategy for anti-AD drug research and development.
project was approved by
Class A strategic pilot science and technology special "personalized drugs - based on the molecular division of diseases of the new drug research and development" and national science and technology major special "major new drug creation" funding. (Source: Voice of the Chinese Academy of sciences)
relevant paper information: